ADC Therapeutics SA, based in Lausanne, Switzerland, has announced the issuance of stock options to two new employees as part of its Inducement Plan. On June 2, 2025, the company granted options to purchase a total of 107,550 common shares. These grants were approved by the Compensation Committee and are structured to vest over a four-year period. Initially, 25% of the options will become exercisable on the first anniversary of the grant date, with an additional 1/48th of the shares vesting monthly thereafter, contingent upon continued employment with the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。